By: Benzinga
UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Dropout Assumptions
In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR ), and raised the price target from $41.00 to $52.00. In the report, Karnauskas noted, “AEGR has made assumptions for dropouts, which are key to their guidance of ending the year
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here